Catheter Precision (NYSEAMERICAN:VTAK) Posts Quarterly Earnings Results, Beats Expectations By $19.51 EPS

Catheter Precision (NYSEAMERICAN:VTAK) posted its quarterly earnings results on Monday. The company reported ($1.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($20.90) by $19.51, FiscalAI reports. The business had revenue of $0.43 million for the quarter, compared to analyst estimates of $1.60 million. Catheter Precision had a negative return on equity of 114.26% and a negative net margin of 2,044.08%.

Catheter Precision Stock Performance

NYSEAMERICAN VTAK traded up $0.07 during trading hours on Monday, hitting $0.83. The company had a trading volume of 446,920 shares, compared to its average volume of 779,692. Catheter Precision has a fifty-two week low of $0.76 and a fifty-two week high of $15.68. The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.46. The business has a fifty day simple moving average of $1.08 and a 200-day simple moving average of $1.68. The firm has a market cap of $2.23 million, a P/E ratio of -0.04 and a beta of -1.04.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC bought a new stake in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision as of its most recent SEC filing. 20.34% of the stock is currently owned by institutional investors and hedge funds.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.